Home » Stocks » Portola Pharmaceuticals

Portola Pharmaceuticals, Inc. (PTLA)

Jul 1, 2020 - PTLA was delisted (reason: acquired by ALXN)
Stock Price: $18.03 USD 0.00 (0.00%)
Updated Jul 2, 2020 4:00 PM EDT

Stock Price Chart

Key Info

Market Cap 1.40B
Revenue (ttm) 120.86M
Net Income (ttm) -281.28M
Shares Out 78.48M
EPS (ttm) -3.78
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 2, 2020
Last Price $18.03
Previous Close $18.03
Change ($) 0.00
Change (%) 0.00%
Day's Open -
Day's Range 17.99 - 18.07
Day's Volume 0
52-Week Range 5.31 - 31.73

More Stats

Market Cap 1.40B
Enterprise Value 1.39B
Earnings Date (est) Aug 11, 2020
Ex-Dividend Date n/a
Shares Outstanding 78.48M
Float 77.64M
EPS (basic) -3.80
EPS (diluted) -3.78
FCF / Share -3.17
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 12.95M
Short Ratio 4.50
Short % of Float 16.68%
Beta 2.31
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 11.61
PB Ratio 19.64
Revenue 120.86M
Operating Income -256.12M
Net Income -281.28M
Free Cash Flow -247.57M
Net Cash 14.77M
Net Cash / Share 0.19
Gross Margin -18.01%
Operating Margin -211.92%
Profit Margin -232.70%
FCF Margin -204.84%
ROA -30.59%
ROE -462.25%
ROIC -48.60%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (4)

Buy 1
Overweight 0
Hold 3
Underweight 0
Sell 0

Analyst Consensus: Overweight

Price Target

(-1.55% downside)
Current: $18.03
Target: 17.75
*Average 12-month price target from 4 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth190.66%77.99%-36.5%194.15%25.4%-8.6%-85.38%-7.67%121.25%-
Gross Profit72.2622.0522.1335.5012.079.6310.5372.0478.0335.27
Operating Income-271-345-273-270-227-138-84.1810.8619.87-18.75
Net Income-291-350-286-269-227-137-83.35-0.08-20.27
Shares Outstanding71.5666.0259.5156.4851.9842.9822.841.351.251.21
Earnings Per Share-4.06-5.31-4.81-4.76-4.36-3.19-3.65-0.06-16.79
Operating Cash Flow-238-326-225-196-207-101-63.62-49.23-11.32-29.65
Capital Expenditures-1.54-2.56-1.24-1.86-4.75-1.63-0.93-0.36-1.48-2.39
Free Cash Flow-239-329-226-198-212-102-64.55-49.59-12.80-32.04
Cash & Equivalents433318463319445309269131188-
Total Debt35221510549.82------
Net Cash / Debt80.73103359269445309269131188-
Book Value13088.40347191427348296-192-206-
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Portola Pharmaceuticals, Inc.
Country United States
Employees 408
CEO J. Scott Garland

Stock Information

Ticker Symbol PTLA
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: PTLA
IPO Date May 22, 2013


Portola Pharmaceuticals, a biopharmaceutical company, develops and commercializes novel therapeutics in the areas of thrombosis, and other hematologic disorders and inflammation in Europe and the United States. Its lead product Andexxa, an antidote for the treatment of rivaroxaban and apixaban under the Ondexxya Brand. The company offers Bevyxxa (betrixaban), an oral, once-daily Factor Xa inhibitor for the prevention of venous thromboembolism in adult patients for an acute medical illness. It also develops cerdulatinib, an investigational oral, dual spleen tyrosine kinase, and janus kinases inhibitor for the treatment of hematologic cancers; and Syk inhibitors. Portola Pharmaceuticals, Inc. has collaboration agreements with Bristol-Myers Squibb; Pfizer Inc.; Daiichi Sankyo, Inc.; Bayer Pharma, AG; Takeda, Ora, Inc.; Astellas Pharma Inc.; and Janssen Pharmaceuticals, Inc. The company was founded in 2003 and is headquartered in South San Francisco, California. As of July 1, 2020, Portola Pharmaceuticals, Inc. operates as a subsidiary of Alexion Pharmaceuticals, Inc.